NZ783166B2 - Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds - Google Patents
Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compoundsInfo
- Publication number
- NZ783166B2 NZ783166B2 NZ783166A NZ78316620A NZ783166B2 NZ 783166 B2 NZ783166 B2 NZ 783166B2 NZ 783166 A NZ783166 A NZ 783166A NZ 78316620 A NZ78316620 A NZ 78316620A NZ 783166 B2 NZ783166 B2 NZ 783166B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- dimethyltryptamine
- acceptable salt
- pharmaceutically acceptable
- dideutero
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
Abstract
The present invention relates to compositions comprising N,N-dimethyltryptamine, deuterated N,N-dimethyltryptamine and/or partially deuterated N,N-dimethyltryptamine. In particular, the present invention relates to compositions comprising a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more deuterated N,N- dimethyltryptamine compound selected from a,a-dideutero-N,N-dimethyltryptamine and a,a,ß,ß-tetradeutero-N,N-dimethyltryptamine. Additional and alternative compositions of the present invention comprise a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more partially deuterated N,N-dimethyltryptamine compound selected from a,ß,ß-trideutero-N,N-dimethyltryptamine, a,ß-dideutero-N,N- dimethyltryptamine, and a-deutero-N,N-dimethyltryptamine. Methods of synthesising compositions of the present invention, and methods of use of presently described compositions in treating psychiatric or psychocognitive disorders, such as major depressive disorder, are also provided.
Claims (14)
1. A composition comprising: (a) an a,a-dideutero-N,N -dimethyltryptamine compound, or a pharmaceutically acceptable salt thereof; (b) an a-protio, a-deutero-N,N -dimethyltryptamine compound, or a pharmaceutically acceptable salt thereof; and (c) N,N -dimethyltryptamine compound, or a pharmaceutically able salt thereof wherein the composition comprises 50% or more by weight of the a,a-dideutero-N,N - yltryptamine compound, or a pharmaceutically acceptable salt thereof, and the io, a-deutero-N,N -dimethyltryptamine compound, or a pharmaceutically acceptable salt thereof.
2. The ition of claim 1, which consists essentially of: (a) a,a-dideutero-N,N-dimethyltryptamine, or a pharmaceutically acceptable salt thereof; (b) a-protio, a-deutero-N,N-dimethyltryptamine, or a pharmaceutically acceptable salt thereof; and (c) N,N-dimethyltryptamine , or a pharmaceutically acceptable salt thereof, wherein the mean molecular weight of a-protio, a-deutero-N,N -dimethyltryptamine, a,adideutero-N ,N -dimethyltryptamine and N,N-dimethyltryptamine present in the composition is from 188.90 to 190.28.
3. The ition of claim 1 or claim 2, comprising 60% or more by weight of the a,a-dideutero-N,N -dimethyltryptamine compound, or a ceutically acceptable salt thereof, and the io, a-deutero-N,N -dimethyltryptamine compound, or a pharmaceutically acceptable salt thereof.
4. The composition of claim 1 or claim 2 wherein the a,a-dideutero-N,N - dimethyltryptamine compound is a,a-dideutero-N,N -dimethyltryptamine, or a pharmaceutically acceptable salt thereof.
5. The composition of any one of claims 1, 3 and 4 comprising an a-protio, ro-N ,N-dimethyltryptamine compound selected from the group consisting of a,ß,ß- 21406236_1 ters) P117886.NZ trideutero-N,N-dimethyltryptamine, a,ß-dideutero-N,N -dimethyltryptamine, and a-protio, a-deutero-N,N -dimethyltryptamine, and pharmaceutically able salts thereof.
6. The composition of any one of claims 1 to 5 comprising a-protio, a-deutero-N,N- dimethyltryptamine, or a pharmaceutically acceptable salt thereof.
7. The composition of any one of claims 1 to 6 having a purity of greater than or equal to 99% by HPLC, optionally a purity of greater than or equal to 99.9% by HPLC.
8. The ition of any one of claims 1 to 7, wherein the a-protio, a-deutero- N,N hyltryptamine and a,a-dideutero-N,N -dimethyltryptamine nds, and N,N-dimethyltryptamine are in the form of a pharmaceutically acceptable salt, optionally wherein the pharmaceutically acceptable salt is a te salt.
9. The composition of any one of claims 1 to 7, wherein the a-protio, a-deutero-N,N - yltryptamine and a,a-dideutero-N,N -dimethyltryptamine compounds, and N,N- yltryptamine are in the form of a fumarate salt.
10. The composition of any one of claims 1 to 9 for use in therapy.
11. Use of the composition of any one of claims 1 to 9 in the manufacture of a medicament for treating a psychocognitive disorder in a patient.
12. The use of claim 11, wherein the psychocognitive disorder is selected from the group consisting of (i) an obsessive compulsive disorder, (ii) a depressive disorder, (iii) an anxiety disorder, (iv) substance abuse, and (v) an avolition disorder.
13. The use of claim 12, wherein the disorder is major depressive disorder, ally wherein the disorder is treatment resistant depression.
14. Use of the ition of any one of claims 1 to 9 in the manufacture of a medicament for dimethyltryptamine-assisted psychotherapy in a patient. 21406236_1 (GHMatters) P117886.NZ A) Plasma B) Effect Site (Brain) 1; 240 "— DMT 1 20 f DMT Spa’CéL ‘x I
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1907871.6A GB201907871D0 (en) | 2019-06-03 | 2019-06-03 | Therapeutic compositions |
| PCT/EP2020/065244 WO2020245133A1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ783166A NZ783166A (en) | 2025-06-27 |
| NZ783166B2 true NZ783166B2 (en) | 2025-09-30 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298542B2 (en) | Therapeutic solid dosage forms comprising deuterated n,n-dimethyltryptamine compounds and salts thereof | |
| IL292753B1 (en) | Compounds, compositions comprising same, and uses thereof in the treatment of psychiatric or neurological disorders | |
| Sarma | Use of ketamine in acute severe asthma | |
| JP2022535093A5 (en) | ||
| RU94045155A (en) | Methods of alzheimer's disease inhibition | |
| JP2012530779A5 (en) | ||
| NO20062691L (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| TW200404808A (en) | Pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds therefor | |
| MXPA04005156A (en) | Adenosine a2a. | |
| MXPA04005209A (en) | ADENOSINE A ??2a? RECEPTOR ANTAGONISTS. | |
| AU2014231722B2 (en) | Salts, co-crystals, and polymorphs of an anxiolytic compound | |
| RU2011146032A (en) | 5-HT4 RECEPTOR AGON COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | |
| AU2023288496A1 (en) | R-mdma crystal forms | |
| WO2001089499A3 (en) | Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer | |
| JP2002528536A (en) | Benzoylpyridazine | |
| NZ783166B2 (en) | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| ATE401082T1 (en) | MEDICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CEREBROVASCULAR DISORDERS | |
| KR20010032009A (en) | Use of mirtazapine for treating sllep apneas | |
| KR20210065948A (en) | α2-adrenergic receptor subtype C (alpha-2C) antagonists for the treatment of sleep apnea | |
| CA2616177C (en) | Imidazolylalkyl-pyridines for the treatment of a sleep disorder | |
| NZ783166A (en) | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| JP2025509830A5 (en) | ||
| KR20000036184A (en) | Use of benzopyranols to treat neurological disorders | |
| JP2022536331A (en) | Treatment of synucleinopathies | |
| NZ794813A (en) | Therapeutic solid dosage forms |